PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy

[1]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[2]  F. Bertucci,et al.  Genomic characterization of metastatic breast cancers , 2019, Nature.

[3]  E. Winer,et al.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Y. Miyoshi,et al.  Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer , 2018, Breast Cancer.

[5]  P. Gibbs,et al.  Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer , 2018, Clinical Cancer Research.

[6]  X. Yi,et al.  Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance , 2018, EBioMedicine.

[7]  M. Koehler,et al.  Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer , 2018, Nature Communications.

[8]  Norikazu Masuda,et al.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[9]  X. Yi,et al.  ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy , 2016, Oncotarget.

[10]  Klaus Pantel,et al.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.

[11]  M. Dowsett,et al.  Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. , 2016, Cancer research.

[12]  A. Özer,et al.  Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer , 2016, Tumor Biology.

[13]  P. Lamy,et al.  Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. , 2015, The Journal of molecular diagnostics : JMD.

[14]  M. Killingsworth,et al.  Gene of the month: PIK3CA , 2015, Journal of Clinical Pathology.

[15]  S Michiels,et al.  Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Lehár,et al.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. , 2014, Cancer cell.

[17]  M. Dowsett,et al.  Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition , 2014, Breast Cancer Research.

[18]  Keda Yu,et al.  PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis , 2014, OncoTargets and therapy.

[19]  R. Salunga,et al.  Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. , 2013, Annals of diagnostic pathology.

[20]  R. Schiff,et al.  Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. , 2013, Breast.

[21]  S. Sleijfer,et al.  Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen , 2013, Breast Cancer Research and Treatment.

[22]  J. Abraham,et al.  Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways , 2013, Expert review of anticancer therapy.

[23]  Ben H. Park,et al.  Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.

[24]  Koichi Goto,et al.  Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  M. Ranson,et al.  Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer , 2010, Breast Cancer Research and Treatment.

[26]  G. Bussolati,et al.  Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.

[27]  D. Hayes,et al.  New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK , 2006, Breast Cancer Research and Treatment.

[28]  Douglas G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK). , 2005, European journal of cancer.

[29]  J. Concato,et al.  Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.